Comparisons9 min readUpdated 2025-09-03

    Hims vs Telehealth Tirzepatide

    Hims vs other telehealth GLP-1 options for 2026: pricing transparency, clinician access model, pharmacy disclosure, refill reliability. How Trimi's $99/mo flat-rate plan compares.

    Written by Trimi Medical Team. Medically reviewed by Dr. Asad Niazi, MD, MPH. This article covers hims vs telehealth tirzepatide including pricing, medication access, support, and practical guidance.

    Quick links: Tirzepatide treatment, Semaglutide treatment.

    Related Resources

    For more information, explore our guides on Tirzepatide, Trimi Pricing Subscription Shipping, Semaglutide, How It Works.

    You can also browse our Cheapest Tirzepatide Provider 2026, Glp1 Complete Guide, Tirzepatide Vs Semaglutide, Semaglutide Weight Loss Results, Buy Tirzepatide Online, Compounded Semaglutide Vs Brand Name guides for additional context.

    Frequently Asked Questions

    What should I know about hims vs telehealth tirzepatide?

    When researching hims vs telehealth tirzepatide, compare pricing transparency, medication access, support quality, refill convenience, and how well each provider fits your personal health goals. These practical factors matter more than brand reputation alone.

    How does Hims compare to Trimi?

    The best choice between Hims and Trimi depends on what you value most: pricing clarity, medication options, clinician support, and how simple the treatment process feels after signup. This is a care-path comparison, not just a medication comparison.

    Which is more affordable, Hims or Trimi?

    Pricing comparison between Hims and Trimi should go beyond headline numbers. Compare how understandable the total cost is, what is included in the monthly price, how dose changes affect cost, and whether there are hidden add-on fees.

    What should I compare between weight loss telehealth providers?

    Compare pricing transparency, medication access and options, support model and communication quality, refill flow and convenience, switching friction, and who each service is designed to serve best. These practical factors matter more than brand reputation alone.

    Who might prefer Hims?

    Some readers may prefer Hims if they already trust the brand, prefer its specific approach to weight loss treatment, or feel comfortable with its intake and delivery model. Hims has its own strengths depending on individual priorities.

    Who might prefer Trimi?

    Some readers may prefer Trimi if they want clearer treatment-specific guidance focused on GLP-1 medications, want a more direct comparison path for weight loss options, or care about pricing clarity and simpler decision support.

    How do I decide which provider is right for me?

    Focus on what matters most to you: if brand familiarity matters, consider Hims. If treatment-specific focus, pricing clarity, and direct GLP-1 guidance matter more, consider Trimi. The best provider fits your priorities and health goals.

    Sources & References

    1. Official provider page: Hims

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any weight loss treatment. Individual results vary. Both semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.

    What does the published clinical evidence show for compounded tirzepatide?

    Peer-reviewed evidence: Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022). Trimi offers compounded tirzepatide starting at $125/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. — SURMOUNT-1, NEJM 2022
    In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. — SURPASS-2, NEJM 2021
    Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. — SURMOUNT-OSA, NEJM 2024

    Key Takeaways

    • Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022)
    • In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. (Source: SURPASS-2, NEJM 2021)
    • Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. (Source: SURMOUNT-OSA, NEJM 2024)
    • Tirzepatide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Zepbound and Mounjaro). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: May 19, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook
    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    Lynn SchweitzerFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2206038
    2. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2107519
    3. Wadden TA, Chao AM, Machineni S, et al. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-023-02597-w
    4. Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2023.24945
    5. Malhotra A, Grunstein RR, Fietze I, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2404881
    6. U.S. Food and Drug Administration (2024). Zepbound (tirzepatide) Prescribing Information. FDA.Read Study

    Was this article helpful?

    Keep Reading

    Hims vs Trimi: side-by-side comparison of pricing, clinician access, pharmacy disclosure, and program structure. Verified 2026 cost data plus how each stacks against Trimi.

    Calibrate vs Telehealth: side-by-side comparison of pricing, clinician access, pharmacy disclosure, and program structure. Verified 2026 cost data plus how each stacks against Trimi.

    Fridays vs Trimi: side-by-side comparison of pricing, clinician access, pharmacy disclosure, and program structure. Verified 2026 cost data plus how each stacks against Trimi.

    Fridays vs Online: side-by-side comparison of pricing, clinician access, pharmacy disclosure, and program structure. Verified 2026 cost data plus how each stacks against Trimi.

    Start your GLP-1 journey — from $99/mo

    Get Started